Research programme: galanin antagonists - Neurogen
Alternative Names: Galanin antagonists research programme - NeurogenLatest Information Update: 10 Jan 2001
At a glance
- Originator Neurogen Corporation
- Class Small molecules
- Mechanism of Action Neurotransmitter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders; Obesity
Most Recent Events
- 10 Jan 2001 Discontinued-Preclinical for Cognition disorders in USA (Unknown route)
- 10 Jan 2001 Discontinued-Preclinical for Obesity in USA (Unknown route)
- 13 Jan 1999 Preclinical development for Obesity in USA (Unknown route)